Mechanistic description
A modifier model is that APOE4 reactive-state signaling, potentially through NF-kB or mTORC1-linked programs, increases SREBP2 activity even when sterol trafficking is not the sole lesion. This is best treated as an amplifier or combination axis rather than the primary explanation for SCAP-SREBP2 dysregulation.
Evidence for (7)
Inflammatory signaling can alter accessible cholesterol and activate canonical SCAP-SREBP processing in other systems.
APOE4 glia commonly exhibit reactive inflammatory phenotypes that could potentiate SREBP2 output.
Tonic prime-boost of STING signalling mediates Niemann-Pick disease type C.
25-Hydroxycholesterol attenuates tumor necrosis factor alpha-induced blood-brain barrier breakdown in vitro.
Relationships of brain cholesterol and cholesterol biosynthetic enzymes to Alzheimer's pathology and dementia in the CFAS population-derived neuropathology cohort.
Neuronal Cholesterol Deficiency Mediated by Astrocytic SREBP2 Downregulation Leads to Postoperative Cognitive Dysfunction Through Impairment of Hippocampal Synaptic Plasticity and Excitatory Synaptic Transmission.
Localization of the transcription factor, sterol regulatory element binding protein-2 (SREBP-2) in the normal rat brain and changes after kainate-induced excitotoxic injury.
Evidence against (3)
There is no clean demonstration of an APOE4-to-NF-kB/mTORC1-to-SREBP2 pathway in astrocytes or microglia.
Inflammation may be downstream of lipid dyshomeostasis rather than the initiating cause of SREBP2 activation.
NF-kB and mTORC1 are broad, toxicity-prone targets with poor standalone trial readiness in neurodegeneration.